Top Industry Leaders in the Osgood Schlatter Market
Latest Osgood-Schlatter Companies Update
Nov 2023: Due to its involvement in a "domestic antitrust cartel" in the United States, the American arm of the massive generic medication manufacturer Teva Pharmaceuticals faces a contract prohibition with the Canadian government that won't expire until the spring of 2025. In October, Teva Pharmaceuticals USA agreed to pay a US$225 million criminal penalty for participating in price-fixing conspiracies involving three pharmaceuticals in the United States. As a result, the company was placed on the Canadian government's list of suppliers ineligible or suspended. The company's local subsidiary, Teva Canada, is exempt from the prohibition, which is only set to expire in April 2025 but may be prolonged. According to a corporate regulatory attorney, it essentially amounts to a reprimand. According to the government's contract database, Teva Canada is currently involved in at least two active contracts. One is valued at more than $3 million and is for "multi-source pharmaceuticals," while the other was granted in July and is for generic medications valued at more than $700,000.
Sep 2023: Last year, the focus shifted from a large orthopedics acquisition to a business split that resulted in a spinoff, but now it is back on substantial dealmaking. Enovis, an independent medical technology company founded a year ago from the portfolio once owned by the Colfax group, has agreed to pay 800 million euros to purchase Lima, an Italian orthopedic implant maker. A cash payment of 700 million euros, or roughly $741 million in US dollars, is part of the deal; the remaining sum is paid in Enovis stock shares. The firms claim that the transaction will create a new billion-dollar participant in the reconstructive operations market, with around half of its revenue coming from the rapidly expanding body-extremity-focused industries. Early in 2024 is when the deal is expected to close.List of Osgood-Schlatter Key companies in the market
- DJO Global, Inc.
- Teva Pharmaceutical Industries Ltd.
- Breg, Inc.
- Bayer HealthCare Pharmaceuticals LLC
- Ossur HF
- Daiichi Sankyo Company, Limited
- Pfizer, Inc.
- Novartis AG